What is the recommended treatment approach for a patient with segmental vitiligo?

Treatment of Segmental Vitiligo

For segmental vitiligo, surgical interventions—particularly split-skin grafting or autologous epidermal suspension—are the first-line treatment for stable disease (no new lesions, no Koebner phenomenon, no extension for ≥12 months), while early-stage or unstable segmental vitiligo should be treated with topical tacrolimus or pimecrolimus combined with narrowband UVB phototherapy. 1

Key Distinction: Segmental Vitiligo is Different

Segmental vitiligo is fundamentally resistant to traditional medical therapies compared to non-segmental vitiligo, making surgical approaches the mainstay of treatment for established disease 2. The unilateral, dermatomal distribution and rapid stabilization pattern distinguish this subtype and dictate a different therapeutic algorithm 3, 4.

Treatment Algorithm by Disease Stage

Early-Stage Segmental Vitiligo (≤5-6 months duration)

Medical therapy can achieve meaningful repigmentation when initiated early:

• Start with topical tacrolimus 0.1% or pimecrolimus twice daily as first-line therapy, avoiding the skin atrophy risk of potent corticosteroids 1
• Add excimer light or narrowband UVB phototherapy if topical therapy alone fails after 2-3 months 5
• Early treatment (within 5-6 months of onset) achieves >75% repigmentation in 50-65% of cases, compared to only 26-44% when treatment is delayed beyond 6 months 5, 4
• Avoid potent topical corticosteroids for >2 months due to atrophy risk, though they may be considered for brief trials 3, 1

Stable Segmental Vitiligo (Surgical Candidates)

All four eligibility criteria must be met before surgical referral: 1

1. No new lesions for ≥12 months
2. No Koebner phenomenon present
3. No extension of existing lesions for ≥12 months
4. Lesion located on cosmetically sensitive site (face, hands, visible areas)

Surgical technique selection (in order of preference):

• Split-skin grafting is the preferred surgical method, achieving >75% repigmentation in 83% of cases with superior cosmetic outcomes 1, 2
• Autologous epidermal suspension applied to laser-abraded lesions followed by NB-UVB or PUVA is considered optimal but requires specialized facilities 1
• Non-cultured cell suspension transplantation (NCST) using expansion ratios of 1:3 to 1:5 provides significantly better repigmentation than higher ratios (1:10), with lower ratios achieving >75% repigmentation more consistently 6
• Cultured keratinocyte grafting achieves good outcomes (≥90% repigmentation) in 60-70% of segmental vitiligo cases after one or more surgeries 7
• Avoid minigraft procedures due to high side-effect rates and poor cosmetic appearance (cobblestone/polka-dot effect) 3, 1

Phototherapy Considerations

If surgery is declined or not feasible:

• NB-UVB phototherapy three times weekly should be reserved for widespread segmental vitiligo or significant quality-of-life impact 3, 1
• NB-UVB is superior to PUVA in efficacy and safety for vitiligo treatment 3
• Limit NB-UVB to 200 treatment sessions for skin types I-III (more restrictive than psoriasis due to absent melanin protection) 3, 1
• PUVA is limited to 150 sessions and not recommended in children 3, 1
• Monitor response with standardized serial photographs every 2-3 months 1

Special Population: Children

• Use tacrolimus or pimecrolimus rather than corticosteroids to prevent steroid-induced atrophy 1
• Excimer light therapy shows excellent results in childhood segmental vitiligo, with 65% achieving >75% repigmentation, particularly when disease duration is <6 months 5
• Surgical interventions are not advised in children due to lack of supporting studies 1

Therapies to Avoid

• Oral dexamethasone should not be used due to unacceptable risk-benefit profile despite theoretical benefit in halting progression 3, 1
• Levamisole has no evidence base for segmental vitiligo and is absent from current treatment guidelines 1
• Minigraft procedures produce poor cosmetic results and high complication rates 3, 1

Common Pitfalls

• Delaying surgical referral in stable disease: Patients meeting all four stability criteria should be referred promptly, as medical therapy has limited efficacy in long-standing segmental vitiligo 2, 4
• Using excessive expansion ratios in cellular grafting: Ratios >1:10 significantly reduce repigmentation success 6
• Prolonged corticosteroid use: Never exceed 2 months of potent topical corticosteroids due to atrophy risk 3, 1
• Missing the early treatment window: Outcomes decline dramatically when treatment is delayed beyond 5-6 months from onset 5, 4

Adjunctive Care

• Offer psychological interventions to address quality-of-life impairment, self-esteem issues, and social anxiety associated with visible depigmentation 1
• Screen for thyroid dysfunction given high prevalence of autoimmune thyroid disease in vitiligo patients 1
• Recommend broad-spectrum sunscreen (physical or chemical based on patient preference) for depigmented areas 1